Inozyme Pharma Inc

Company Profile

Inozyme Pharma Inc had its IPO on 2020-07-24 under the ticker symbol INZY.

The company operates in the Healthcare sector and Biotechnology industry. Inozyme Pharma Inc has a staff strength of 56 employees.

Stock update

Shares of Inozyme Pharma Inc opened at $4.73 at the start of the last trading session i.e. 2023-09-12.

The stocks traded within a range of $4.64 - $4.93, and closed at $4.7.

This is a -1.47% slip from the previous day's closing price.

A total volume of 633,648 shares were traded at the close of the day’s session.

In the last one week, shares of Inozyme Pharma Inc have slipped by -2.69%.

Inozyme Pharma Inc's Key Ratios

Inozyme Pharma Inc has a market cap of $298.15 million, indicating a price to book ratio of 0.3806 and a price to sales ratio of 0.

In the last 12-months Inozyme Pharma Inc’s revenue was $0 with a gross profit of $0 and an EBITDA of $-70405000. The EBITDA ratio measures Inozyme Pharma Inc's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Inozyme Pharma Inc’s operating margin was 0% while its return on assets stood at -28.45% with a return of equity of -53.31%.

In Q2, Inozyme Pharma Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 0%.

Inozyme Pharma Inc’s PE and PEG Ratio

Forward PE

0

Trailing PE

0

PEG

Its diluted EPS in the last 12-months stands at $-1.56 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Inozyme Pharma Inc’s profitability.

Inozyme Pharma Inc stock is trading at a EV to sales ratio of 0 and a EV to EBITDA ratio of 1.2394. Its price to sales ratio in the trailing 12-months stood at 0.

Inozyme Pharma Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets

$150.93 million

Total Liabilities

$12.08 million

Operating Cash Flow

$-16327000.00

Capital Expenditure

$11000

Dividend Payout Ratio

0%

Inozyme Pharma Inc ended 2024 with $150.93 million in total assets and $0 in total liabilities. Its intangible assets were valued at $150.93 million while shareholder equity stood at $105.59 million.

Inozyme Pharma Inc ended 2024 with $0 in deferred long-term liabilities, $12.08 million in other current liabilities, 5000.00 in common stock, $-247748000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $40.85 million and cash and short-term investments were $140.25 million. The company’s total short-term debt was $862,000 while long-term debt stood at $31.88 million.

Inozyme Pharma Inc’s total current assets stands at $143.59 million while long-term investments were $0 and short-term investments were $99.40 million. Its net receivables were $0 compared to accounts payable of $2.01 million and inventory worth $0.

In 2024, Inozyme Pharma Inc's operating cash flow was $-16327000.00 while its capital expenditure stood at $11000.

Comparatively, Inozyme Pharma Inc paid $0 in dividends in 2024.

Other key metrics

Current Trading Price

$4.7

52-Week High

$7.33

52-Week Low

$0.991

Analyst Target Price

$20.83

Inozyme Pharma Inc stock is currently trading at $4.7 per share. It touched a 52-week high of $7.33 and a 52-week low of $7.33. Analysts tracking the stock have a 12-month average target price of $20.83.

Its 50-day moving average was $5.26 and 200-day moving average was $4.14 The short ratio stood at 2.86 indicating a short percent outstanding of 0%.

Around 90.9% of the company’s stock are held by insiders while 8479.8% are held by institutions.